Search

everythinglearnresearchcommunity

for

Search:↓

Women experience more side effects and have worse blood pressure control from hypertension treatments than men, despite using different medications.

PCOS affects about 4% of women in the southeastern U.S. equally across Black and White populations.

PCOS affects a similar percentage of Black and White women in the Southeastern United States.

The guideline refines PCOS diagnosis, promotes a healthy lifestyle, reviews treatments, and stresses long-term follow-up.

Sex hormones like estrogen and testosterone may affect COVID-19 severity differently in men and women, potentially influencing prevention and treatment strategies.

Acne affects most teenagers and can continue into adulthood, with various treatments available that show improvement but have concerns like antibiotic resistance and side effects.

Testosterone replacement can help women with low libido and mood, but they need to have enough estrogen first to avoid side effects.

Amenorrhea is relatively rare and initial testing should check FSH, TSH, and prolactin levels.

The conclusion is to diagnose PCOS with just hyperandrogenism and irregular periods, and treat with lifestyle changes and basic medications.

Combined oral contraceptives improve skin, hormone levels, and quality of life in women with PCOS.

The document concludes that identifying the cause of amenorrhea is crucial for proper treatment.

Testosterone replacement therapy can prevent men from fathering children and should not be used by those wanting to stay fertile.

Cyproterone acetate is the preferred treatment for women's hyperandrogenism when estrogen/progestogen use is safe.

Common skin conditions can greatly affect a person's mental health and social life.

New treatments for low male hormones improved sexual function and mood but had unclear risks, especially for older men.

Combining letrozole with metformin is the most effective treatment for inducing pregnancy in women with PCOS.

Topical minoxidil is the best-supported treatment for female hair loss, but personalized plans are needed.

Long-term estrogen therapy in postmenopausal women can improve certain health markers, hair loss is common regardless of hormone use, stopping estrogen doesn't increase breast cancer risk, smoking does, and a balanced BMI is linked to lower mortality.

Smoking may contribute to hair loss in men.

Testosterone therapy can improve sexual satisfaction and mood in surgically menopausal women when used with estrogen, but its long-term safety and effects on naturally menopausal and premenopausal women are unclear.

The conclusion is that effectively treating hair disorders is difficult due to the complex factors affecting hair growth and more research is needed to improve treatments.

MENT could be a better option than testosterone for male hormone therapy and birth control because it works well at lower doses and has fewer side effects on the prostate.

Androgens are important for female fertility and could help in IVF treatment, but also play a role in causing PCOS.

Adalimumab is the most effective treatment for severe hidradenitis suppurativa, but more research is needed to improve treatment options.

Women's ovarian hormones and adrenal androgens change throughout life, affecting hair loss and health.

The document concludes that Rabson-Mendenhall syndrome requires novel treatments for insulin resistance and emphasizes the importance of dental care in affected patients.

Eating disorders can cause various hair problems, and while hair loss in these disorders is linked to metabolic syndrome, treatment focuses on specific medications and lifestyle changes for the syndrome.

Many men misuse oral contraceptive pills for things like hair growth and muscle gain.

Amenorrhea, or the absence of periods, should be evaluated by age 15 or within five years of early breast development, and is most commonly caused by conditions like polycystic ovary syndrome and hypothalamic amenorrhea.

Amenorrhea is when a woman doesn't have periods, with primary amenorrhea starting by age 15 or within five years of breast development, and secondary amenorrhea when periods stop for three months. It affects 3-4% of women not pregnant, breastfeeding, or in menopause, mainly due to polycystic ovary syndrome, hypothalamic amenorrhea, hyperprolactinemia, and ovarian failure.